Pub. Date : 2003 Mar
PMID : 12601049
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. | Budesonide | vascular endothelial growth factor A | Homo sapiens |
| 2 | PURPOSE: The purpose of this study was to determine whether budesonide inhibits expression of vascular endothelial growth factor (VEGF) in a retinal pigment epithelial cell line (ARPE-19) and to determine whether subconjunctivally administered budesonide nano- and microparticles sustain retinal drug levels. | Budesonide | vascular endothelial growth factor A | Homo sapiens |
| 3 | PURPOSE: The purpose of this study was to determine whether budesonide inhibits expression of vascular endothelial growth factor (VEGF) in a retinal pigment epithelial cell line (ARPE-19) and to determine whether subconjunctivally administered budesonide nano- and microparticles sustain retinal drug levels. | Budesonide | vascular endothelial growth factor A | Homo sapiens |
| 4 | RESULTS: At concentrations devoid of cytotoxicity, budesonide inhibited VEGF secretion as well as mRNA expression in ARPE-19 cells in a dose-dependent manner. | Budesonide | vascular endothelial growth factor A | Homo sapiens |
| 5 | RU486 treatment prevented budesonide-mediated inhibition of VEGF secretion and VEGF mRNA expression. | Budesonide | vascular endothelial growth factor A | Homo sapiens |
| 6 | RU486 treatment prevented budesonide-mediated inhibition of VEGF secretion and VEGF mRNA expression. | Budesonide | vascular endothelial growth factor A | Homo sapiens |
| 7 | CONCLUSIONS: Budesonide is capable of inhibiting VEGF expression through glucocorticoid receptor activity. | Budesonide | vascular endothelial growth factor A | Homo sapiens |